Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Number of Adverse Drug Reactions

Outcome Time Frame:

Patients with gastric ulcer, anastomotic ulcer or Zollinger-Ellison syndrome: 8 weeks

Safety Issue:

Yes

Principal Investigator

Shigeru Yoshida, MD

Investigator Role:

Study Director

Investigator Affiliation:

Astrazeneca K.K.

Authority:

Japan: Ministry of Health, Labor and Welfare

Study ID:

D961HC00010

NCT ID:

NCT01434485

Start Date:

September 2011

Completion Date:

December 2013

Related Keywords:

• Gastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer, Reflux Oesophagitis,"Non-erosive Reflux Disease, Zollinger-Ellison Syndrome
• gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux oesophagitis, non-erosive reflux disease, Zollinger-Ellison syndrome, Nexium
• Duodenal Ulcer
• Esophagitis
• Esophagitis, Peptic
• Gastroesophageal Reflux
• Stomach Ulcer
• Ulcer
• Zollinger-Ellison Syndrome
• Gastrinoma